Given that our evidence suggests that all the effects of the RARα system will be equally down-regulated by Aβ in AD because it inhibits the synthesis of the endogenous agonist, RA, it would therefore be expected that all the effects would be a return towards normality. This evidence concerns the gene RARA and Alzheimer disease.